Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

Herwig Ulf Meier-Kriesche, Bettina J. Steffen, Alan M. Hochberg, Robert D. Gordon, Michael N. Liebman, Jonathan A. Morris, Bruce Kaplan

    Research output: Contribution to journalArticlepeer-review

    110 Scopus citations

    Abstract

    To evaluate the association of long-term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, we analyzed 47 693 primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998. The primary study endpoint was acute rejection beyond 1 year after transplantation. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. All multivariate analyses were corrected for potential confounding covariates. Mycophenolate mofetil was associated with a 65% decreased risk of developing late acute rejection as compared to AZA (RR = 0.35, Cl 0.27-0.45, p < 0.001). The incidence of acute rejection episodes at 2 and 3 years post-transplantation was significantly lower in the MMF group (0.9% at 2 years, 1.1% at 3 years) than the AZA group (6.1 % at 2 years, 9.3% at 3 years). In the primary vs. repeat late rejection analysis, MMF patients exhibited a decreased late acute rejection risk of 72% (RR=0.28, p < 0.001) and 60%, respectively (RR=0.40, p < 0.001). In African Americans, the late acute rejection risk was 70% lower in MMF patients than AZA patients (RR = 0.30, p < 0.001). Further study is indicated to determine the optimal duration of MMF therapy after renal allograft transplantation.

    Original languageEnglish (US)
    Pages (from-to)68-73
    Number of pages6
    JournalAmerican Journal of Transplantation
    Volume3
    Issue number1
    DOIs
    StatePublished - Jan 2003

    Keywords

    • Acute rejection
    • Azathioprine
    • Immunosuppression
    • Kidney transplantation
    • Mycophenolate mofetil

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Transplantation
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection'. Together they form a unique fingerprint.

    Cite this